Checkpoint inhibitors in mesothelioma: hope for the future?

Bibby, Anna; Maskell, Nick A

doi:10.1016/s1470-2045(18)30868-4

Cited by 5 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety profile observed was consistent with known data for this combination regimen, and was well tolerated. At the time of reporting, median OS had not yet been reached but was estimated, with 95% confidence, to exceed 12.7 months (58).…”

Section: Combination Therapymentioning

confidence: 98%

Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives

Gray¹,

Mutti²

2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

At the clinical level the role of immunotherapy in cancer is currently at a pivotal point. Therapies such as checkpoint inhibitors are being approved at many levels in cancers such as non-small cell lung cancer (NSCLC). Mesothelioma is a rare orphan disease associated with prior exposure to asbestos, with a dismal prognosis. Various clinical trials for checkpoint inhibitors have been conducted in this rare disease, and suggest that such therapies may play a role as a treatment option for a proportion of patients with this cancer.Most recently approved as a salvage therapy in mesothelioma was granted in Japan, regulatory approval for their use in the clinic elsewhere lags. In this article we review the current pertinent clinical trials of immunotherapies in malignant mesothelioma, discuss the current issues that may affect the clinical outcomes of such therapies and further evaluate potential candidate new avenues that may become future targets for immunotherapy in this cancer.

show abstract